Mayo Clinic scientists propose a breast cancer drug for bladder cancer patients Oct. 08, 2014 Overview Mostrar la transcripción Overview Researchers at Mayo Clinic have found amplification of HER2, a known driver of some breast cancers, in a type of bladder cancer called micropapillary urothelial carcinoma (MPUC), has shown that the presence of HER2 amplification is associated with particularly aggressive tumors. These findings suggest that administering trastuzumab to MPUC patients with HER2 amplification could improve outcomes, just as it has for breast cancer. The study is published in Modern Pathology. VID-20450111 Profesionales médicos Mayo Clinic Scientists Propose a Breast Cancer Drug for Bladder Cancer Patients